Study Points
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.
Study Points
Click on any objective to view test questions.
Which is important to keep in mind regarding drug transporter systems (e.g., P-glycoprotein [P-gp])?
Click to ReviewWe are still learning about the significance of these transporters on pharmacokinetics. Most of the available data are related to P-glycoprotein (P-gp, multidrug resistance protein 1 [MDR1]). P-gp is a drug efflux pump found in the gut, liver, kidney, blood-brain barrier, and cancer cells. It pumps drugs out of cells and into the gut, bile, and/or urine for excretion [6]. Other examples include BCRP, which pumps drugs out of cells in the gut, liver, and kidney, and OATPs (e.g., OATP1B1, OATP1B3), which move drugs into the liver [5].
Which drug transport system has the most available data related to its effects on drug pharmacokinetics?
Click to ReviewWe are still learning about the significance of these transporters on pharmacokinetics. Most of the available data are related to P-glycoprotein (P-gp, multidrug resistance protein 1 [MDR1]). P-gp is a drug efflux pump found in the gut, liver, kidney, blood-brain barrier, and cancer cells. It pumps drugs out of cells and into the gut, bile, and/or urine for excretion [6]. Other examples include BCRP, which pumps drugs out of cells in the gut, liver, and kidney, and OATPs (e.g., OATP1B1, OATP1B3), which move drugs into the liver [5].
Which pair of direct oral anticoagulants are significantly metabolized by CYP3A4?
Click to ReviewGenerally, CYP450 interactions and drug transporter interactions involve substrates, inhibitors, and inducers. Inhibitors may increase levels of CYP450 or P-gp substrates, and inducers may decrease levels of CYP450 or P-gp substrates. For many interactions, CYP450 enzyme inhibition or induction is also involved, and P-glycoprotein substrates are often also CYP3A4 substrates, so the contribution of P-gp inhibition/induction versus CYP450 inhibition/induction can be difficult to discern [7,8,9]. For example, apixaban and rivaroxaban are metabolized by CYP3A4 (Table 1), and absorption of all DOACs is affected by P-glycoprotein (Table 2) [2,10].
Which of the following medications is a strong inhibitor of CYP3A4?
Click to ReviewSELECT CYP450-3A4 PATHWAY DRUG INTERACTIONS
DOAC Substratesc Select Inhibitors Select Inducers Apixaban Rivaroxaban Amiodarone Amlodipine Atazanavira Cimetidine Ciprofloxacina Clarithromycinb Cobicistatb Conivaptana Cyclosporinea Diltiazema Dronedaronea Erythromycina Ethinyl estradiol Fluconazolea Fluoxetine Fluvoxaminea Fosamprenavira Grapefruitb Indinavirb Isoniazid Itraconazoleb Ketoconazoleb Lansoprazole Lopinavir/ritonavirb Mifepristone Nefazodoneb Nelfinavirb Nicardipine Posaconazoleb Ritonavirb Saquinavir/ritonavirb Ticagrelor Tipranavir/ritonavirb Verapamila Voriconazoleb Voxelotor Carbamazepine Modafinil Nafcillin Nevirapine Oxcarbazepine Phenobarbital Phenytoin Rifabutin Rifampin Rifapentine St. John's wort Topiramate aModerate inhibitors (≥2 to <5-fold increase in exposure, or 50% to 80% decrease in clearance of substrate). For many medications, strength of inhibition in vivo is undetermined. bStrong inhibitors (≥5-fold increase in exposure or >80% decrease in clearance of substrate) cDabigafran is not a substrate, inducer, or inhibitor of CYP450 enzymes. Edoxaban is only minimally metabolized by CYP450. Which of the following medications is a strong inducer of P-gp?
Click to ReviewSELECT P-GLYCOPROTEIN DRUG INTERACTIONS
DOAC Substrates Select Inhibitors Select Inducersa Apixaban Dabigatran Edoxaban Rivaroxaban Amiodarone (moderate or strong inhibitor) Atorvastatin Azithromycin Canagliflozin (weak inhibitor) Captopril Carvedilol Clarithromycinc (strong inhibitor) Cobicistat Conivaptanb Cyclosporineb (strong inhibitor) Diclofenac Diltiazemb Dronedaroneb (strong inhibitor) Erythromycinb (strong inhibitor) Esomeprazole Ibuprofen Indomethacin Itraconazolec Ketoconazolec (strong inhibitor) Lansoprazole Lopinavir/ritonavirc Lovastatin Mirabegron Naproxen Nefazodonec Nelfinavirc Nifedipine Omeprazole Posaconazolec Propafenone Quinidine (strong inhibitor) Quinine Rabeprazole Ranolazine Ritonavirc Saquinavir/ritonavirc Simvastatin Spironolactone Telmisartan Tetracycline Ticagrelor Trimethoprim Tipranavir/ritonavirc Verapamilb (strong inhibitor) Vilazodone Voriconazole (strong inhibitor) Carbamazepine Phenobarbital Phenytoin Rifabutin Rifampin St. John's wort Venlafaxine aAll are strong inducers, except venlafaxine. bModerate CYP3A inhibitors cStrong CYP3A inhibitors Which medication is most likely to decrease levels of a DOAC and increase thrombosis risk?
Click to ReviewDrug experts from Pharmacist's Letter and Prescriber Insights provide the following practical approach to managing DOAC interactions [11]:
Pinpoint critical DOAC interactions, and act if necessary.
Generally avoid combining DOACs with strong CYP3A4 and P-glycoprotein inducers (e.g., phenytoin, rifampin, St. John's wort). These may lower DOAC levels and increase thrombosis risk.
If these interacting medications cannot be avoided, switch to warfarin, because it is easier to monitor than a DOAC.
Watch for strong CYP3A4 and P-glycoprotein inhibitors (e.g., ritonavir, itraconazole), as these may raise DOAC levels and increase bleeding risk.
Which of the following medications is most likely to raise levels of a direct oral anticoagulant (DOAC) and increase bleeding risk?
Click to ReviewDrug experts from Pharmacist's Letter and Prescriber Insights provide the following practical approach to managing DOAC interactions [11]:
Pinpoint critical DOAC interactions, and act if necessary.
Generally avoid combining DOACs with strong CYP3A4 and P-glycoprotein inducers (e.g., phenytoin, rifampin, St. John's wort). These may lower DOAC levels and increase thrombosis risk.
If these interacting medications cannot be avoided, switch to warfarin, because it is easier to monitor than a DOAC.
Watch for strong CYP3A4 and P-glycoprotein inhibitors (e.g., ritonavir, itraconazole), as these may raise DOAC levels and increase bleeding risk.
Which of the following statements regarding DOAC interactions with nirmatrelvir/ritonavir is TRUE?
Click to ReviewTo manage these drug interactions, consider the specific DOAC, dose, and indication (Table 3). One example that blends consideration of these factors is use of nirmatrelvir/ritonavir for treatment of COVID-19 in patients receiving a DOAC. This combination introduces potential risk for drug interactions, because ritonavir is a strong CYP3A4 and P-glycoprotein inhibitor. For instance, when a patient is receiving nirmatrelvir/ritonavir for COVID-19, apixaban being given for atrial fibrillation should be reduced to 2.5 mg twice per day during treatment and for three days after. However, coadministration of nirmatrelvir/ritonavir and rivaroxaban should be avoided [12].
What is advised for patients receiving apixaban for venous thromboembolism treatment if a strong CYP3A4 and P-gp inducer is required?
Click to ReviewCOMPARISON OF DOACs
Drug Approved Indications and Dosing (Adults) Select Interactions Apixaban (Eliquis) Thromboembolism (e.g., stroke) prevention in nonvalvular atrial fibrillation: 5 mg BID or 2.5 mg BID for patients with ≥2 of the following:
Age ≥80 years
Weight ≤60 kg
Serum creatinine ≥1.5 mg/dL
VTE prevention post-hip or knee replacement: 2.5 mg BID for 35 days (hip) or 12 days (knee) starting 12 to 24 hours post-operative DVT/PE treatment: 10 mg BID for seven days, then 5 mg BID DVT/PE prevention of recurrence: 2.5 mg BID after at least six months of treatment Atrial fibrillation: A reasonable anticoagulant choice for patients with CrCl <15 mL/min or on dialysis Reduce dose by 50% with strong inhibitors of both CYP3A4 and P-gp (e.g., itraconazole, ketoconazole, ritonavir). Avoid in patients already taking 2.5 mg BID. Resume usual dose three days after the last dose of nirmatrelvir/ritonavir (Paxlovid). Avoid strong inducers of both CYP3A4 and P-gp (e.g., phenobarbital, carbamazepine, phenytoin, St. John's wort, rifampin). Caution with antiplatelets and anticoagulants. Dual antiplatelet therapy about doubles bleeding risk. Dabigatran (Pradaxa) Thromboembolism (e.g., stroke) prevention in nonvalvular atrial fibrillation: 150 mg BID DVT/PE treatment (following 5 to 10 days' treatment with a parenteral anticoagulant) or prevention of recurrence: 150 mg BID. Start 0 to 2 hours before the next dose of parenteral anticoagulant would have been due, or at the time of discontinuation of heparin drip. VTE prevention post-hip replacement: 220 mg once daily for 28 to 35 days. If started on day of surgery (1 to 4 hours post-surgery, assuming hemostasis achieved), initial dose is 110 mg. Atrial fibrillation: Use 75 mg BID if CrCl 15 to 30 mL/min. No dosing information for CrCl <15 mL/min or dialysis. DVT/PE treatment/prevention (adults) and VTE prevention post-hip replacement: No dosing information for CrCl ≤30 mL/min or dialysis P-gp inhibitors may increase dabigatran levels. For atrial fibrillation indication: Avoid P-gp inhibitors (e.g., amiodarone) if CrCl <30 mL/min. Reduce dose to 75 mg BID with ketoconazole or dronedarone if CrCl 30–50 mL/min. For VTE/PE treatment/prevention (including post-hip replacement): Avoid use of P-gp inhibitors if CrCl <50 mL/min. Consider separating by several hours if CrCl ≥50 mL/min (hip replacement indication). P-gp inducers could decrease dabigatran efficacy. Avoid P-gp inducers per labeling. Use caution with antiplatelets. Co-administration with aspirin or clopidogrel about doubles bleeding risk. Drugs that increase gastric pH could reduce efficacy. Take dabigatran at least two hours before antacids. Edoxaban (Savaysa) Thromboembolism (e.g., stroke) prevention in nonvalvular atrial fibrillation: 60 mg once daily in patients with CrCl 50 to ≤95 mL/min DVT/PE treatment (following 5 to 10 days' treatment with a parenteral anticoagulant): 60 mg once daily, or 30 mg once daily if body weight ≤60 kg Atrial fibrillation: 60 mg once daily for CrCl 50 to ≤95 mL/min, or 30 mg once daily for CrCl 15–50 mL/min. Not for use in patients with CrCl 95 mL/min. DVT/PE treatment: 30 mg once daily for CrCl 15–50 mL/min (after 5 to 10 days of parenteral anticoagulant) Not recommended if CrCl <15 mL/min Use with other anticoagulants is not recommended, except when switching. Caution with antiplatelets. Can use with aspirin ≤100 mg/day, with caution. Avoid rifampin (a P-gp inducer). Reduce dose to 30 mg once daily for DVT/PE indication in patients taking certain P-gp inhibitors (e.g., azithromycin, clarithromycin, erythromycin, itraconazole [oral], ketoconazole [oral], quinidine, verapamil). Rivaroxaban (Xarelto) VTE prevention post-hip or knee replacement: 10 mg once daily for 35 days [hip] or 12 days [knee] starting 6 to 10 hours post-surgery, assuming hemostasis achieved. Avoid if CrCl <15 mL/min. Thromboembolism (e.g., stroke) prevention in nonvalvular atrial fibrillation: 20 mg once daily with evening meal to improve absorption. Dose is 15 mg with evening meal for CrCl ≤50 mL/min. Consider rivaroxaban 10 mg or 15 mg once daily in patients undergoing hemodialysis based on pharmacokinetic and limited clinical outcome data. DVT/PE treatment or prevention of recurrence: 15 mg BID (with food to improve absorption) for three weeks, then 20 mg once daily with food for at least six months, then 10 mg once daily. Avoid if CrCl <15 mL/min. VTE prevention in acutely ill medical patients at risk for VTE but without high risk of bleeding: 10 mg once daily for 31 to 39 days. Avoid if CrCl <15 mL/min. Cardiovascular risk reduction in patients with CAD or PAD: 2.5 mg BID, with aspirin 75–100 mg once daily. (Patients with eGFR <15 mL/min were excluded from clinical trial, and <1% of included patients had eGFR <30 mL/min.) Avoid use with drugs that are both P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, posaconazole, ritonavir, cobicistat). In patients with CrCl 15 to <80 mL/min, the decision to use a combined P-gp/moderate CYP3A4 inhibitor (e.g., erythromycin) is a risk/benefit determination. Avoid with amiodarone or verapamil if CrCl is <80 mL/min. Drugs that are P-gp and strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort) may decrease efficacy and should be avoided. Avoid use with other anticoagulants. Caution with antiplatelets, including clopidogrel. BID = twice per day, CAD = coronary artery disease, CrCl = creatinine clearance, DVT = deep vein thrombosis, eGFR = estimated glomerular filtration rate, PAD = peripheral arterial disease, PE = pulmonary embolism, VTE = venous thromboembolism. What is generally advised for patients receiving apixaban for stroke prevention in atrial fibrillation and aspirin for cardiovascular primary prevention?
Click to ReviewCaution should be exercised when prescribing DOAC and medications that increase the risk of bleeding (e.g., antiplatelets, non-steroidal anti-inflammatory drugs [NSAIDs]). Ensuring the need for both agents is the first step. For example, aspirin used for cardiovascular primary prevention can usually be discontinued; aspirin for cardiovascular primary prevention is no longer routinely recommended, regardless of DOAC use [13; 14]. Duration of combination therapy is another concern. For instance, clopidogrel can be discontinued one-year post-stent placement for most patients with atrial fibrillation on a long-term DOAC. Limited evidence suggests that DOAC monotherapy is often sufficient at this point [15].
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.